Carregant...
Benefit–risk evaluation: the past, present and future
In the last two decades there has been a shift in the approach to evaluating the benefit–risk (BR) profiles of medicinal products from an unstructured, subjective, and inconsistent, to a more structured and objective, process. This article describes that shift from a historical perspective; the past...
Guardat en:
| Publicat a: | Ther Adv Drug Saf |
|---|---|
| Autor principal: | |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
SAGE Publications
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6712756/ https://ncbi.nlm.nih.gov/pubmed/31489173 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2042098619871180 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|